Navigation Links
First noninvasive technique to accurately predict mutations in human brain tumors
Date:4/20/2009

DENVER Donald O'Rourke, MD, Associate Professor of Neurosurgery at the University of Pennsylvania School of Medicine and colleagues, were able to accurately predict the specific genetic mutation that caused brain cancer in a group of patients studied using magnetic resonance imaging (MRI). The researchers presented their findings this week at the American Association for Cancer Research 100th Annual Meeting 2009.

"The field of cancer research has evolved to the point where the identification of the mutations that cause tumors has changed how we treat patients in a number of cancers," says O'Rourke. "Potentially, we believe we have a method that uses MRI to identify a tumor mutation. Historically tumor mutations have been identified in only one way: take the tissue out and examine it using one of two laboratory tests to see if the mutation is present. In this study we've done this identification noninvasively. To my knowledge this is the first demonstration that an MRI, or any imaging technique, can accurately predict the type of mutation of a human tumor."

A particular MRI technique, called relative cerebral blood volume that measures blood flow to the tumor, very highly correlates with the presence of an important mutation in glioblastoma, a type of brain cancer. The mutation occurs in the epidermal growth factor receptor, EGFR, a well known cancer-related protein that helps tumors form their necessary blood vessels. EGFRvIII, the specific mutation the Penn group studied, is the hallmark of a more aggressive form of glioblastoma.

The research team compared MRI readings to tumor tissue samples from 97 glioblastoma patients. They found that patients with higher relative cerebral blood volume as measured by MRI correlates with the EGFRvIII mutation compared to those who did not have the mutation.

Glioblastoma is a variable disease, and clinicians need help to distinguish one form from another. "All of cancer research is evolving to a point where mutations can facilitate care, so a more accurate diagnosis and treatment course can be better planned by identifying the mutational status of the tumor," says O'Rourke.

EGFRvIII is an area of intense interest in the field of cancer, being associated with more aggressive cancers. Having a noninvasive way to identity patients with the EGFRvIII mutation could allow physicians to enroll these patients into trials using drugs that specifically target this mutation. Penn is part of a multicenter trial that is doing just that.

Another implication of having a noninvasive method to track a specific patient group is for following treatment response. "Currently we identify a tumor mutation by removing a tumor, and then we select a particular treatment and evaluate the response with an MRI to see if the tumor is stable or smaller," explains O'Rourke. "With this new method we'll be able to show whether a surrogate of the mutation is changing. EGFRvIII correlates with the elevated blood flow to the tumor and if we put a patient on an effective anti-tumor strategy, that blood flow should reduce. We'd be getting a more biological readout to therapy."

Ongoing work focuses on using advanced MRI to characterize additional mutations in glioblastoma tumors.


'/>"/>

Contact: Karen Kreeger
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Sitting at the Virtual Poker Table: Results From First Ever Epidemiological Study of Actual Internet Poker Gaming Behavior, in Press
2. IPC The Hospitalist Company, Inc. to Report First Quarter 2009 Financial Results
3. Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
4. Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter
5. First Annual World Meningitis Day Gaining National Support
6. Lilly Reports Strong First-Quarter 2009 Results
7. First Woman President of the AVMA to Speak at Ross University School of Veterinary Medicine's 2009 Graduation
8. U.S. Venture Investment Lowest in 11 Years, Down 50% to $3.9 Billion in First Quarter
9. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
10. Pennsylvania Governors Food Safety Council to Hold First Meeting on April 22
11. Caliper Life Sciences First Quarter 2009 Financial Results Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... , ... “Fred Rides a Train” allows readers to tag along on a ... a Train” is the creation of published author, Janet Morrison, who has been writing ... The "Fred, the Dog" series is her first attempt at writing for children. Janet, ...
(Date:12/7/2016)... San Mateo, CA (PRWEB) , ... December 07, 2016 , ... ... entire San Francisco Peninsula region, is proud to announce new city-specific pages as part ... care services for the elderly, they often look, first, for local agencies serving their ...
(Date:12/6/2016)... , ... December 06, 2016 , ... ... dysfunction because of a higher risk of serious health problems, such as cardiovascular ... Star2.com. Dr. Peiman Soleymani of Beverly Hills Periodontics & Dental Implant Center notes ...
(Date:12/6/2016)... California (PRWEB) , ... December 06, 2016 , ... ... management (PHM) technology, has named Ajdin Camaga as a vice president of sales. ... says Justin Neece, president. “He works hard to understand what each client needs, ...
(Date:12/6/2016)... ... December 06, 2016 , ... In anticipation for the New ... the availability of continuing education courses in 2017, dentists of all levels can continue ... Beginning in January, dentists can attend a variety of continuing education courses each month ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Calif. , Dec. 6, 2016 /PRNewswire/ ... held, clinical-stage medical dermatology and aesthetics company, ... a privately held specialty pharmaceutical company focused ... inflammatory skin conditions, including psoriasis, atopic dermatitis ... the agreement, Sienna will make an undisclosed ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Blueprint Medicines ... discovering and developing targeted kinase medicines for patients with ... an underwritten public offering of $125,000,000 million in shares ... to grant the underwriters a 30-day option to purchase ... of its common stock in connection with the public ...
(Date:12/6/2016)... Dec. 6, 2016  In response to the tragic ... every 25 minutes, a respected group of local and ... provide a holistic suite of services to help Medicaid-eligible ... on his own experience trying to help family and ... Justin Lanning launched 180 Health Partners ...
Breaking Medicine Technology: